|Videos|May 23, 2022
Role of Neurooncologists in Management of HER2+ Breast Cancer and Brain Metastases
A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.
Advertisement
Advertisement
Related to this article
Six-year NATALEE data show ribociclib plus an NSAI reduced the risk of death by 19% vs NSAI alone in HR+/HER2- early breast cancer.
Final NSABP B-42 data show 5 additional years of letrozole improved DFS, BCFI, and distant recurrence vs placebo at 15 years, with no OS difference.
Hope S. Rugo, MD, FASCO, and Irene M. Kang, MD, discussed ASCENT-03, -04, and TROPION-Breast02 data, sequencing, and toxicity in metastatic TNBC.
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection.
“What has changed is that we are bringing the phase 1 trials earlier in the course of treatment for our patients,” said Oana Danciu, MD.
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, PANKU-Breast01, and VIKTORIA-1.
Nikolai Strusberg, MD, discussed other toxicities of proton vs photon breast RT, practice implications, and next steps in capsular contracture research.
Nikolai Strusberg, MD, explained the clinical hypothyroidism endpoint and how thyroid dose should guide proton vs photon choice in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Perioperative Pembrolizumab Plus Chemo Does Not Significantly Improve EFS in MIBC
2
Adjuvant Ribociclib Improves OS at 6 Years in HR+/HER2- Early Breast Cancer
3
Top Poster Takeaways for Prostate Cancer From 2026 ESMO Congress
4
Extended Letrozole Sustains DFS Benefit at 15 Years in HR+ Breast Cancer
5